Phesgo and Tecentriq Performance and Approvals
Portfolio rejuvenation progressing; new launches with >50% of sales
Columvi (glofitamab): first NME launch in 2023*
Roche
CHFM
% of Pharma Sales***
7,000
ENSPRYNG
50%
PHESGO
6,000
susvimo
LUXTURNA
voretigene neparvovec-rzyl
xofluza
Evrysdi.
ranibizumab injection
5,000
42%
risdiplama
TECENTRIQ™
atezolizumab
VENCLEXTA
POLIVY
planbedde
HEMLIBRA
emicizumab-kxwh
GAVRETO
RONAPREVE
casinivinab and indevinab
4,000
VABYSMO
Lunsumic
31%
mosunetuzumab
3,000
22%
COLUMVI
guftame
2,000
ALECENSA
alectinib
OCREVUS
ocrelizumab
ROZLYTREK
1,000
COTELLIC
0
2016 | 2017 | 2018 | 2019 | 2020 2021 2022
2023
Q1 2020
Q1 2021
Q1 2022
Q1 2023
Expected NME
Launches:
⚫ crovalimab
⚫ SRP-9001
Cotellic
Alecensa
Luxturna
Xofluza
Tecentriq
Polivy
Ocrevus
Hemlibra
Rozlytrek
Enspryng
Phesgo
Evrysdi
Gavreto
Ronapreve
Susvimo
Vabysmo
Lunsumio
*First launch in Canada, PDUFA date in the US is July 1st; ** SRP-9001: Accelerated US-filing by partner company Sarepta; crovalimab: First filing in China;' *Venclexta sales booked by AbbVie and therefore not included
10
10View entire presentation